According to FDA’s What’s New Related to Drugs, on February 16, CDER published Guidance Agenda: New & Revised Draft Guidances CDER is Planning to Publish During Calendar Year 2017. Here’s a link to the document and here is a link to contact us with your drug development concerns.
Pharmaceutical Development Group (PDG) is a subsidiary of Biotech Research Group Corporation.
PDG
Pharmaceutical Development Group
- Home
- Services
- Pharmaceutical Consulting Services
- Strategic Drug Development
- Strategic Drug Development Services
- Pharmaceutical Development Programs: Implementation and Oversight
- Pre-IND Meetings
- Investigational New Drug Application (IND)/Special Protocol Assessment (SPA)
- Clinical Trial Design
- Pre-NDA Meetings and NDA Submissions: 505(b)(1)/505(b)(2)
- 505(b)(2) NDAs
- Generic Drugs: 505(j) ANDAs and Potential Diversification
- Nonprescription Drugs (OTC)
- Medical Device Consulting
- Post-Launch Activities
- Specialty Services
- Regulatory Updates
- About PDG
- Regulatory Resources
- Contact PDG
- Home
- Services
- Pharmaceutical Consulting Services
- Strategic Drug Development
- Strategic Drug Development Services
- Pharmaceutical Development Programs: Implementation and Oversight
- Pre-IND Meetings
- Investigational New Drug Application (IND)/Special Protocol Assessment (SPA)
- Clinical Trial Design
- Pre-NDA Meetings and NDA Submissions: 505(b)(1)/505(b)(2)
- 505(b)(2) NDAs
- Generic Drugs: 505(j) ANDAs and Potential Diversification
- Nonprescription Drugs (OTC)
- Medical Device Consulting
- Post-Launch Activities
- Specialty Services
- Regulatory Updates
- About PDG
- Regulatory Resources
- Contact PDG
CDER Announces New & Revised Draft Guidances to be Published During Calendar Year 2017
You are here:
- Home
- Breaking News
- CDER Announces New & Revised…